AZN · NYSE · CIK 0000901832

ASTRAZENECA PLC

ASTRAZENECA PLC’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 27, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $58.7B and net income of $10.2B, according to its XBRL data on EDGAR. Its EDGAR record lists 7 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$58.7B
Net income, FY2025
$10.2B
Form 4 filings on record, past 12 months
7

Company overview

Legal name (as filed)
ASTRAZENECA PLC
Ticker
AZN
SEC Central Index Key (CIK)
0000901832
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
CAMBRIDGE
State or country of incorporation
United Kingdom
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#47 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from ASTRAZENECA PLC’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$37.4BFY2021$44.4BFY2022$45.8BFY2023$54.1BFY2024$58.7BFY2025
Net income
$115.0MFY2021$3.3BFY2022$6.0BFY2023$7.0BFY2024$10.2BFY2025
AZN annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$37.4B$44.4B$45.8B$54.1B$58.7B
Net income$115.0M$3.3B$6.0B$7.0B$10.2B
Diluted EPS$0.08$2.11$3.81$4.50$6.54
Total assets$105.4B$96.5B$101.1B$104.0B$114.1B
Cash and equivalents$1.5B$1.4B$1.3B$1.2B$1.3B

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

AZN latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 24, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 27, 20266-KENHERTU APPROVED IN EU FOR HER2-POSITIVE EBC· period Oct 27, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about ASTRAZENECA PLC, by form type:

6-K ×374 ×3
AZN recent filings
FiledFormWhat it isOriginal
Oct 27, 20266-KENHERTU APPROVED IN EU FOR HER2-POSITIVE EBC· period Oct 27, 2026Document · Index
Oct 22, 20266-KULTOMIRIS APPROVED IN US IN IGAN· period Oct 22, 2026Document · Index
Oct 8, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 6, 2026Document · Index
Oct 5, 20266-KASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT· period Oct 5, 2026Document · Index
Oct 2, 20266-KAZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY· period Oct 2, 2026Document · Index
Oct 1, 20266-KADMISSION OF FURTHER SECURITIES TO TRADING· period Oct 1, 2026Document · Index
Oct 1, 20266-KTOTAL VOTING RIGHTS· period Oct 1, 2026Document · Index
Sep 29, 20266-KASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT· period Sep 29, 2026Document · Index
Sep 23, 20266-KTRIXEO APPROVED IN EU FOR ASTHMA· period Sep 23, 2026Document · Index
Sep 21, 20266-KKLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP· period Sep 21, 2026Document · Index
Sep 21, 20266-KENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC· period Sep 21, 2026Document · Index
Sep 18, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Sep 18, 2026Document · Index
Sep 15, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Sep 15, 2026Document · Index
Sep 15, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Sep 15, 2026Document · Index
Sep 14, 20266-KUPDATE ON SERENA-4 PHASE III TRIAL· period Sep 14, 2026Document · Index
Sep 11, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 8, 2026Document · Index
Sep 8, 20266-KIMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG· period Sep 8, 2026Document · Index
Sep 8, 20266-KETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER· period Sep 8, 2026Document · Index
Sep 1, 20266-KADMISSION OF FURTHER SECURITIES TO TRADING· period Sep 1, 2026Document · Index
Sep 1, 20266-KTOTAL VOTING RIGHTS· period Sep 1, 2026Document · Index
Sep 1, 20266-KADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING· period Sep 1, 2026Document · Index
Sep 1, 20266-KENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC· period Sep 1, 2026Document · Index
Sep 1, 20266-KDIRECTORATE CHANGE· period Sep 1, 2026Document · Index
Sep 1, 20266-KASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY· period Sep 1, 2026Document · Index
Sep 1, 20266-KTAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG· period Sep 1, 2026Document · Index
Aug 27, 20266-KTEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS· period Aug 27, 2026Document · Index
Aug 25, 20266-KASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING· period Aug 25, 2026Document · Index
Aug 19, 20266-KDIRECTOR/PDMR SHAREHOLDING· period Aug 19, 2026Document · Index
Aug 17, 20266-KENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER· period Aug 17, 2026Document · Index
Aug 17, 20266-KUPDATE ON EVOLVE-LUNG02 PHASE III TRIAL· period Aug 17, 2026Document · Index
Aug 17, 20266-KTAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG· period Aug 17, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 6, 2026Document · Index
Aug 3, 20266-KADMISSION OF FURTHER SECURITIES TO TRADING· period Aug 3, 2026Document · Index
Aug 3, 20266-KTOTAL VOTING RIGHTS· period Aug 3, 2026Document · Index
Jul 31, 20266-KDATROWAY APPROVED IN EU FOR TNBC· period Jul 31, 2026Document · Index
Jul 27, 20266-KUPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA· period Jul 27, 2026Document · Index
Jul 27, 20266-KSONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS· period Jul 27, 2026Document · Index
Jul 27, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jul 23, 20266-KETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER· period Jul 23, 2026Document · Index
Jul 14, 20266-KASTRAZENECA LICENSES NOVEL EGFR INHIBITOR· period Jul 14, 2026Document · Index

Insider filing activity

7 Form 4 filings appear in ASTRAZENECA PLC’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000901832 and XBRL company facts. ASTRAZENECA PLC on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.